GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LumiraDx Ltd (OTCPK:LMDWF) » Definitions » Stock Based Compensation

LumiraDx (LumiraDx) Stock Based Compensation : $27.77 Mil (TTM As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is LumiraDx Stock Based Compensation?

LumiraDx's Stock Based Compensation for the three months ended in Jun. 2023 was $1.95 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2023 was $27.77 Mil.


LumiraDx Stock Based Compensation Historical Data

The historical data trend for LumiraDx's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LumiraDx Stock Based Compensation Chart

LumiraDx Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Stock Based Compensation
3.97 3.19 33.91 35.21

LumiraDx Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.44 9.58 8.22 8.02 1.95

LumiraDx Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $27.77 Mil.


LumiraDx Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of LumiraDx's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


LumiraDx (LumiraDx) Business Description

Traded in Other Exchanges
Address
C/o Ocorian Trust (Cayman) Ltd, Windward 3, P.O. Box 1350, Regatta Office Park, Grand Cayman, CYM, KY1-1108
LumiraDx Ltd is a next-generation point of care diagnostics company. It manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. Geographical presence in United States, Italy, UK, Germany, Colombia, Sweden and Other countries. Majority revenue derives from U.S.